0 followers
Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients’ true risk of disease progression.
Marie Labus
Exscientia
2 followers
Immunocore
1 follower
Capricor Therapeutics
1 follower
Elicio Therapeutics
1 follower
Balderton Capital
65 followers
Outlier Ventures
5 followers
PolyAI
5 followers
Artiva Biotherapeutics
1 follower
Thermo Fisher Scientific
159 followers
Roivant Sciences
56 followers
SkyBridge U.K. Ltd
2 followers
Explore companies